Second, P selectin antagonism may be a valuable treatment for stroke prevention, particularly in high-risk PAR4 Thr120-positive patients, such as in sickle-cell disease, where approximately 40% and approximately 47% of patients are expected to have AA and AG genotypes, respectively. This evidence concerns the gene F2RL3 and Stroke.